In the global competitive landscape of coronary and peripheral vascular interventional devices, the treatment of vascular calcified lesions is a core sub-segment. The three main technical approaches include Rotational Atherectomy (RA), Excimer Laser Coronary Angioplasty (ELCA), and Intravascular Lithotripsy (IVL). These approaches vary significantly in terms of lesion adaptability, technical barriers, and the layout strategies of domestic and overseas manufacturers. The RA track is technically mature, with overseas leaders such as Boston Scientific and Abbott having significant first-mover advantages. MicroPort’s domestic rotational devices have achieved technical parity and are gradually replacing imports. The ELCA track is a niche supplementary solution, with Philips maintaining a long-term market monopoly. IVL represents a blue ocean segment in the industry. Although overseas brand Shockwave holds a dominant position, HuiHe Medical’s C-Wave system, China’s first lithotripsy system approved for both coronary and peripheral vascular indications, offers exclusive local technical advantages.
With overseas giants such as Boston Scientific, Abbott, and Philips, along with domestic innovators like HuiHe Medical and Saihe Medical, each building their competitive edge through unique core technologies, comprehensive product lines, complete clinical evidence data, and localized medical services, they collectively drive continuous technological advancement in vascular lesion modification devices.
Looking ahead, competition in the RA and ELCA markets will become more normalized, while the IVL segment will become the core growth area of the industry. Domestic original devices like HuiHe Medical will open up new growth opportunities. The mature commercial operations of global leaders and the localized innovation approaches of Chinese companies serve as model examples for industry development. Mutual learning between them can promote balanced development in coronary and peripheral vascular intervention, supporting long-term sustainable expansion.
In the global competitive landscape of coronary and peripheral vascular interventional devices, the management of vascular calcified lesions constitutes the core sub-track, which is divided into three major technical routes: Rotational Atherectomy (RA), Excimer Laser Coronary Angioplasty (ELCA), and Intravascular Lithotripsy (IVL). These routes differ markedly in lesion adaptability, technical barriers, and the layout strategies of domestic and overseas manufacturers. The RA track is technically mature, with overseas leaders Boston Scientific and Abbott enjoying prominent first-mover advantages, while domestic rotational devices developed by MicroPort have achieved technical parity and are gradually realizing import substitution. The ELCA track serves as a niche supplementary solution, with Philips maintaining long-term market monopoly. IVL represents the blue ocean track of the industry. Though overseas brand Shockwave holds a dominant position, HuiHe Medical’s C-Wave system, China’s first lithotripsy system approved for both coronary and peripheral vascular indications, boasts exclusive localized technical strengths.
Overseas giants including Boston Scientific, Abbott, and Philips, as well as domestic innovators represented by HuiHe Medical and Saihe Medical, have built differentiated competitiveness through route-specific core technologies, comprehensive product pipelines, complete clinical evidence databases and localized medical services, collectively driving continuous technological iteration in the field of vascular lesion modification devices.
Looking ahead, competition in the RA and ELCA markets will enter a normalized stage, whereas the IVL track will emerge as the core growth engine of the industry. Original domestic devices exemplified by HuiHe Medical will unlock brand-new growth potential. The mature commercial operation systems of global giants and the localized innovation paths of Chinese manufacturers serve as mutual industry benchmarks. Mutual reference between the two parties can foster balanced development of the coronary and peripheral vascular intervention industry and support its long-term sustainable expansion.
If you have further research needs regarding China’s cardiovascular interventional device market, please contact us:
Frost & Sullivan Jing Jing
E-mail: jing.jing@frostchina.com
